Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.

Hematology. American Society of Hematology. Education Program - 6 Dec 2024

Heuser Michael, Shahswar Rabia

Abstract excerpt

Acute myeloid leukemia (AML) is classified by risk groups according to a number of genetic mutations, which may occur alone or in combination with other mutations and chromosomal abnormalities. Prognosis and appropriate therapy can vary significantly based on a patient's genetic risk group, making mutation-informed decisions crucial to successful management. However, the presence of measurable residual disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplasm, Residual

Source

Open in PubMed Open full text

Identifiers

PMID: 39644001
DOI: 10.1182/hematology.2024000542
PMCID: PMC11665733

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.PMID 39644001Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Biomarkers and advances in AML-MRC: from bench to bedside.Semantic proximity Read ↗

Novel Tools for Diagnosis and Monitoring of AML.Semantic proximity Read ↗

MRD evaluation of AML in clinical practice: are we there yet?Semantic proximity Read ↗

How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsSemantic proximity Read ↗

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterSemantic proximity Read ↗

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.